SecBot SecBot
SECBOTREPLAY Home › Report › BMY

BMY · Bristol Myers Squibb reported Q2 2026 results significantly above…

BRISTOL MYERS SQUIBB CO · 8-K filed Jul 30, 2026 at 07:05 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 30, 2026 at 07:05 ET

Bristol Myers Squibb reported Q2 2026 results significantly above consensus, with non-GAAP EPS of $2.04 beating the $1.60 estimate by 27.7% and revenue of $13.0B exceeding the $11.74B consensus. The company raised its full-year 2026 revenue guidance to $49.0B-$50.0B (from $46.0B-$47.5B) and non-GAAP EPS guidance to $6.75-$7.00 (from $6.05-$6.35), driven by 15% Growth Portfolio revenue growth and broad-based momentum.

  • Q2 2026 total revenues of $12.973B, up 6% YoY (+5% Ex-FX), vs consensus $11.74B
  • Non-GAAP EPS of $2.04, up 40% YoY from $1.46, beating consensus of $1.60 by 27.7%
  • GAAP EPS of $1.62, up 153% YoY from $0.64
  • Growth Portfolio revenues of $7.6B, up 15% YoY (+14% Ex-FX), driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access